Chapter 31: Adrenergic Antagonists

Chapter 31 offers an in-depth exploration of adrenergic antagonists, commonly referred to as sympatholytic drugs, which therapeutically block or lyse the effects of the sympathetic nervous system (SNS). The clinical utility and associated adverse effects of these medications are fundamentally tied to their receptor-site specificity, meaning their affinity for various alpha or beta receptor subtypes. These blocking agents ultimately result in vital physiological responses, including lowered blood pressure, a slower pulse rate, and enhanced renal perfusion alongside decreased renin levels. The chapter details four major classes: Nonselective adrenergic blocking agents (e.g., carvedilol, labetalol) block both alpha and beta receptors and are typically used to manage cardiac-related conditions like hypertension and heart failure (HF). Nonselective alpha-adrenergic blocking agents like phentolamine block both alpha-1 and alpha-2 receptors, leading to vasodilation and reduced blood pressure, often accompanied by undesirable reflex tachycardia; phentolamine is particularly vital for preventing dermal necrosis after intravenous extravasation of catecholamines (like norepinephrine). In contrast, Alpha1-selective adrenergic blocking agents (e.g., doxazosin, prazosin) block only the postsynaptic alpha1-receptors, effectively lowering blood pressure through vasodilation without triggering reflex tachycardia. These agents are frequently used to treat hypertension and benign prostatic hyperplasia (BPH) due to their relaxing effects on the smooth muscle in the bladder and prostate. Among the beta-blockers, Nonselective beta-adrenergic blocking agents (e.g., propranolol) block both beta1 and beta2 receptors. Although useful for angina, hypertension, migraines, and essential tremor, this widespread blockade carries a significant risk of respiratory distress and bronchospasm because it prevents the normal compensatory sympathetic bronchodilation. Consequently, Beta1-selective adrenergic blocking agents (e.g., atenolol, metoprolol) are often the preferred choice for patients with respiratory issues (like COPD or asthma), as they maintain crucial beta2-mediated bronchodilation at therapeutic doses. A key nursing consideration applicable to all adrenergic blocking agents is the critical requirement to taper the medication slowly over several weeks, as abrupt discontinuation after chronic use can sensitize receptors to catecholamines, potentially precipitating severe and life-threatening events such as myocardial infarction (MI), stroke, or extreme hypertension. Patients must be monitored closely for common adverse effects involving the CNS (dizziness, fatigue), CV system (bradycardia, hypotension), and potential masking of typical hypoglycemia signs in diabetic patients.